Optimal Regimen in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-05-31

Study Completion Date

2015-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Clopidogrel resistance is common in patients of ischemic cerebrovascular disease.
2. Genetic polymorphisms are the most important factors to clopidogrel resistance.
3. The purpose of this study is to find the genes which are the related to clopidogrel resistance.
4. Through gene sequencing, we can filter patient of clopidogrel resistance, so another drug maybe used to avoid the undesired efficacy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genotype Guided Antiplatelet Therapy in Ischemic Stroke

NCT05763862

Ischemic Stroke Transient Ischemic Attack

RECRUITING NA

The Dynamic Effect of Non-cytochrome P450 Isoenzyme 3A4（CYP3A4）-Metabolized and Cytochrome P450 Isoenzyme 3A4（CYP3A4）-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction

NCT02411903

Cerebral Infarction Clopidogrel,Poor Metabolism of (Disorder)

UNKNOWN PHASE4

The Influence of CYP2C19 Polymorphism and Clinical Outcomes in Stroke Patients

NCT02711410

Platelet Aggregation Inhibitors

COMPLETED

Biomarkers of Clopidogrel Resistance for Predicting Ischemic Recurrence After Cerebral Artery Stenting

NCT07028775

Ischemic Stroke

NOT_YET_RECRUITING

Clopidogrel Preventive Effect Based on CYP2C19 Genotype in Ischemic Stroke

NCT04072705

Acute Ischemic Stroke

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Cerebrovascular Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* symptomatic ischemic cerebrovascular disease caused by Intracranial atherosclerotic atherosclerosis research database.
* 90 days had a stroke or transient ischemic attack is defined as symptomatic Intracranial atherosclerotic atherosclerosis
* stenosis ≥ 50% (MRI or CT angiography).
* Intracranial vascular stenosis measured according to the method reported Warfarin aspirin symptomatic intracranial disease research.

Exclusion Criteria

* diffuse intracranial arterial stenosis.
* cranial magnetic resonance imaging shows lesions as the branch artery blockage caused.
* non-atherosclerotic lesions.
* occurred within 6 weeks of vascular lesions in the region of intracranial hemorrhage.
* potential cardiac thrombus source.
* has concurrent intracranial tumors, intracranial aneurysm or arteriovenous malformation.
* ipsilateral extracranial carotid or vertebral artery stenosis ≥ 50%;
* known to heparin, aspirin, clopidogrel, anesthetics and contrast agents contraindications;
* hemoglobin less than 10g/dL, platelet count \<100000/dL;
* responsibility left after cerebral vascular-related serious neurological dysfunction (mRS ≥ 3);
* international normalized ratio\> 1.5
* there are factors that can not be corrected by bleeding;
* life expectancy \<1 year;
* pregnant or lactating women;
* indications Commission determines that the patient is not suitable for the study treatment.

Minimum Eligible Age

25 Years

Maximum Eligible Age

95 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No